Cynthia Sears, MD | |
600 N Wolfe St, Baltimore, MD 21287-0005 | |
(410) 955-1725 | |
Not Available |
Full Name | Cynthia Sears |
---|---|
Gender | Female |
Speciality | Internal Medicine - Infectious Disease |
Location | 600 N Wolfe St, Baltimore, Maryland |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1558386995 | NPI | - | NPPES |
526331000 | Medicaid | MD |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RI0200X | Internal Medicine - Infectious Disease | D37017 (Maryland) | Primary |
Entity Name | Johns Hopkins University |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
The big noise on the health insurance front today was sounded by Target, which announced via a corporate blog that it's ending health insurance for its part-time workers. Instead of signing up for a company plan, they're encouraged to use the health care exchanges set up through the Affordable Care Act. ...
New results from The Environmental Determinants of Diabetes in the Young study show an association between prolonged enterovirus infection and the development of autoimmunity to the insulin-producing pancreatic beta-cells that precedes type 1 diabetes.
Par Pharmaceutical Companies, Inc. today announced that it (and its subsidiary Par Pharmaceutical and development partner MN Pharmaceuticals of Turkey) has entered into a settlement agreement with sanofi-aventis that resolves patent litigation related to its generic version of sanofi's and Debiopharm's Eloxatin® (oxaliplatin injection) product, a drug used to treat colorectal cancer, in the U.S. District Court for the District of New Jersey.
The Critical Path Institute, an independent, non-profit organization that works to accelerate the speed of drug and medical product development, today announced it has received a three-year grant renewal from the Bill & Melinda Gates Foundation.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Cynthia Sears, MD Po Box 64264, Baltimore, MD 21264-4264 Ph: () - | Cynthia Sears, MD 600 N Wolfe St, Baltimore, MD 21287-0005 Ph: (410) 955-1725 |
News Archive
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
The big noise on the health insurance front today was sounded by Target, which announced via a corporate blog that it's ending health insurance for its part-time workers. Instead of signing up for a company plan, they're encouraged to use the health care exchanges set up through the Affordable Care Act. ...
New results from The Environmental Determinants of Diabetes in the Young study show an association between prolonged enterovirus infection and the development of autoimmunity to the insulin-producing pancreatic beta-cells that precedes type 1 diabetes.
Par Pharmaceutical Companies, Inc. today announced that it (and its subsidiary Par Pharmaceutical and development partner MN Pharmaceuticals of Turkey) has entered into a settlement agreement with sanofi-aventis that resolves patent litigation related to its generic version of sanofi's and Debiopharm's Eloxatin® (oxaliplatin injection) product, a drug used to treat colorectal cancer, in the U.S. District Court for the District of New Jersey.
The Critical Path Institute, an independent, non-profit organization that works to accelerate the speed of drug and medical product development, today announced it has received a three-year grant renewal from the Bill & Melinda Gates Foundation.
› Verified 6 days ago
Dr. Leonard Anang Sowah, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-706-4619 Fax: 410-706-2062 | |
Dr. Bhavandeep Singh Bajaj, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 3345 Wilkens Avenue, Suite L10, Baltimore, MD 21229 Phone: 410-644-4444 Fax: 410-644-4484 | |
Dr. Yonas Sisay, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 822 Guilford Ave, #100, Baltimore, MD 21202 Phone: 410-385-9672 | |
Dr. Stephen John Witanowski, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 2700 Quarry Lake Dr, Suite 280, Baltimore, MD 21209 Phone: 410-469-5544 Fax: 410-585-2867 | |
Dr. Susrutha Kotwal, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4940 Eastern Ave, Mfl Bldg, West Tower, 6th Floor, Baltimore, MD 21224 Phone: 410-550-5018 | |
Dr. Mitesh G Trambadia, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 6701 N Charles St Ste 5218, Baltimore, MD 21204 Phone: 443-849-3786 | |
Ronak K Patel, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 201 E University Pkwy, Baltimore, MD 21218 Phone: 410-554-2000 |